“The United States is essentially inventing the technology and then the rest of the world is figuring out how to use it better,” he said.

The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough. 

A new study shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in CT and PET/CT images than physicians.

This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.

Researchers examined data from nearly 5,400 patients, tracking such outcomes as myocardial infarction, stroke and all-cause mortality. 

This is the fourth device in Medtronic's Evolut TAVR platform. The self-expanding valve gained FDA approval in 2021 for the treatment of high- and low-risk patients presenting with symptomatic severe aortic stenosis.

Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.